CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories Inc. /DE/ (CLB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS SECOND QUARTER 2026 RESULTS: • REVENUE OF $124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR • OPERATING INCOME OF $9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR • GAAP EARNINGS
How this was made
The 30-second read
Why it matters
Traders can update near-term expectations for revenue and margins based on reported Q2 metrics, segment margin commentary, and management’s stated view that Q3 should see sequential improvement as conditions normalize.
Market read
A primary quarterly results disclosure with specific financial figures, segment drivers, and capital return actions that can move positioning into Q3.
What to watch
The margin drivers include a modest benefit from recovery of certain tariffs, so underlying operating leverage may be less favorable than headline ex-items strength suggests.
Background
The 8-K (Item 2.02) reports Core Laboratories’ Q2 2026 results and discusses segment performance for Reservoir Description and Production Enhancement, attributing weakness to geopolitical conflicts.
Ticker impact
Core Laboratories reported Q2 2026 revenue of $124.6M, GAAP EPS $0.13, and $3.1M free cash flow, plus a $2.7M share repurchase.
Likely modest, two-sided reaction depending on how investors weigh geopolitical headwinds versus sequential improvement and the repurchase.
The filing is a primary earnings-style disclosure with specific datapoints (revenue, operating income, EPS, FCF) and management commentary on Middle East and Russia-Ukraine disruptions, plus a concrete buyback and dividend announcement.
Market effects
Provides read-through on demand resilience for reservoir characterization and completion diagnostics amid ongoing energy infrastructure disruptions.
Highlights Middle East suspension effects and mentions improving activity in Africa, U.S., and Asia-Pacific.
Reinforces that Russia-Ukraine sanctions and shipping-route disruptions can directly affect international lab networks and assay activity.
Counterpoint
Sequential improvement may be partially offset by temporary disruptions; investors could discount the Q3 outlook if geopolitical normalization timing is uncertain.
Key entities
- companyCore Laboratories Inc. /DE/
NYSE-listed provider of reservoir characterization and completion diagnostic services; reported Q2 2026 results and announced a dividend and share repurchase.
- executiveLarry Bruno
CEO quoted in the release, attributing results to sequential improvement despite geopolitical disruptions.
- customerMurphy Oil Corporation
Named as engaging Core Lab for a reservoir characterization program offshore Côte d’Ivoire.
